MedTrace Logo

Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis

NCT01191996 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2012-12-07

No results posted yet for this study

Summary

The purpose of the study is to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously administered MIS416 weekly in patients with chronic progressive multiple sclerosis.

Conditions

Interventions

BIOLOGICAL

MIS416

MIS416 intravenously every week

Sponsors & Collaborators

  • Primorus Clinical Trials

    collaborator UNKNOWN

  • National Multiple Sclerosis Society

    collaborator OTHER

  • Innate Immunotherapeutics

    lead INDUSTRY

Principal Investigators

  • Alison Luckey · Primorus Clinical Trials

  • Tim Anderson · Department of Medicine, University of Otago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2012-06-30
Completion
2012-11-30

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01191996 on ClinicalTrials.gov